Supercharged immune cells take on resistant blood cancers

NCT ID NCT06930651

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new type of immune cell therapy for people with myeloid cancers (like AML or MDS) that have come back or not responded to treatment. The cells are taken from donated cord blood, engineered to better recognize and attack cancer cells, and given after chemotherapy. The main goals are to find a safe dose and see if the treatment can shrink or control the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TGFBR2 KO CAR.70/IL-15 NK cells (a type of immune cell engineered to target cancer and resist suppression)
What this could lead to: If it works, this could point toward a new treatment option for patients with hard-to-treat myeloid cancers that have not responded to standard therapies.
What could go wrong: This is an early phase 1/2 trial with only 42 participants, so the main goal is safety and dosing, not proof of effectiveness. The treatment may cause side effects or fail to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA-1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia chronic myelomonocytic leukemia myelodysplastic syndrome myeloid neoplasm therapy related acute myeloid leukemia and myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOID MALIGNANCIES

Contacts and locations

Locations

The University of Texas M. D. Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.